Advertisement

Journal of Neural Transmission

, Volume 109, Issue 3, pp 393–398 | Cite as

Combined analysis of CSF βA42 peptide and tau protein and serum antibodies to glycosaminoglycans in Alzheimer's disease: preliminary data

  • C. Briani
  • S. Ruggero
  • M. Naccarato
  • A. Cagnin
  • G. L. Ricchieri
  • L. Pasqui
  • G. Pizzolato
  • L. Battistin

Summary.

Neuropathological hallmarks of Alzheimer's disease (AD) are amyloid plaques and neurofibrillary tangles, containing βA42 peptide and tau protein, respectively. Amyloid plaques contain also glycosaminoglycans (GAGs). Whereas cerebrospinal fluid (CSF) levels of βA42 peptide and tau protein have been demonstrated as potential markers of Alzheimer's disease (AD), no data are available for GAGs. We determined (Elisa) tau and βA42 CSF levels, as well as serum antibodies to GAGs in 9 AD patients, and the values were analyzed in relation to age and severity of the disease. Beta-A42 and tau CSF levels were significantly reduced and increased, respectively, in AD patients when compared to controls, but they did not correlate with the severity of the disease. Despite their role in amyloidogenesis, we did not find evidence for the use of GAGs as diagnostic marker of AD.

Keywords: Alzheimer tau βA42 CSF glycosaminoglycans. 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Copyright information

© Springer-Verlag Wien 2002

Authors and Affiliations

  • C. Briani
    • 1
  • S. Ruggero
    • 1
  • M. Naccarato
    • 1
  • A. Cagnin
    • 1
  • G. L. Ricchieri
    • 1
  • L. Pasqui
    • 1
  • G. Pizzolato
    • 1
  • L. Battistin
    • 1
  1. 1.Department of Neurological and Psychiatric Sciences, University of Padua, ItalyIT

Personalised recommendations